Annals of Vascular Surgery
Volume 21, Issue 6 , Pages 719-722 , November 2007

Risk of Heparin-Induced Thrombocytopenia from Heparin-Bonded Vascular Prostheses

  • Leila Mureebe

      Affiliations

    • Division of Vascular Surgery, New York Presbyterian Hospital, New York, NY
    • Corresponding Author InformationCorrespondence to: Leila Mureebe, MD, Division of Vascular Surgery, New York Presbyterian Hospital, Columbia University Medical Center, 5141 Broadway, Suite 3-169, New York, NY 10034, USA
    • ,
  • Joseph A. Graham

      Affiliations

    • Division of Vascular Surgery, University of Missouri Health Care, Columbia, MO
    • ,
  • Ruth L. Bush

      Affiliations

    • Division of Vascular Surgery, Texas A & M University Health Science Center, Scott & White Memorial Hospital and Clinic, Temple, TX
    • ,
  • Donald Silver

      Affiliations

    • Division of Vascular Surgery, University of Missouri Health Care, Columbia, MO

References 

  1. Iba T, Shin T, Sonoda T, et al. Stimulation of endothelial secretion of tissue-type plasminogen activator by repetitive stretch. J Surg Res. 1991;50:457–460
  2. Iba T, Sumpio BE. Tissue plasminogen activator expression in endothelial cells exposed to cyclic strain in vitro. Cell Transplant. 1992;1:43–50
  3. Lawrie GM, Weilbacher DE, Henry PD. Endothelium-dependent relaxation in human saphenous vein grafts. Effects of preparation and clinicopathologic correlations. J Thorac Cardiovasc Surg. 1990;100:612–620
  4. Pereira CE, Albers M, Romiti M, et al. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44:510–517
  5. Begovac PC, Thomson RC, Fisher JL, et al. Improvements in GORE-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg. 2003;25:432–437
  6. Gott VL, Whiffen JD, Dutton RC. Heparin Bonding on Colloidal Graphite Surfaces. Science. 1963;vol. 142:1297–1298
  7. Serruys PW, Emanuelsson H, van der Giessen W, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation. 1996;93:412–422
  8. Xue L, Greisler HP. Biomaterials in the development and future of vascular grafts. J Vasc Surg. 2003;37:472–480
  9. Esquivel CO, Bjorck CG, Bergentz SE, et al. Reduced thrombogenic characteristics of expanded polytetrafluoroethylene and polyurethane arterial grafts after heparin bonding. Surgery. 1984;95:102–107
  10. Becquemin JP, Riff Y, Kovarsky S, et al. Evaluation of a polyester collagen-coated heparin bonded vascular graft. J Cardiovasc Surg. 1997;38:7–14
  11. Almeida JI, Liem TK, Silver D. Heparin-bonded grafts induce platelet aggregation in the presence of heparin-associated antiplatelet antibodies. J Vasc Surg. 1998;27:896–901
  12. Devine C, Hons B, McCollum C. Heparin-bonded Dacron or polytetrafluoroethylene for femoropopliteal bypass grafting: a multicenter trial. J Vasc Surg. 2001;33:533–539
  13. Devine C, McCollum C. North West Femoro-Popliteal Trial. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial. J Vasc Surg. 2004;40:924–931
  14. Laster J, Silver D. Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg. 1988;7:667–672
  15. Calaitges JG, Liem TK, Spadone D, et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg. 1999;29:779–786
  16. Almeida JI, Coats R, Liem TK, Silver D. Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. J Vasc Surg. 1998;27:309–316
  17. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res. 1998;89:41–50
  18. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998;91:916–922
  19. Ao PY, Hawthorne WJ, Coombs R, Fletcher JP. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model. Int Angiol. 1999;18:131–139
  20. Ao PY, Hawthorne WJ, Taylor DA, Fletcher JP. Optimal dose and duration of heparin for inhibition of intimal hyperplasia. Int Angiol. 1997;16:94–100
  21. Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003;15:11–18
  22. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol. 1999;46:151–208
  23. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia—a review. J Vasc Surg. 1991;13:885–891
  24. Berk BC, Gordon JB, Alexander RW. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17(6 Suppl B):111B–117B
  25. Lambert AW, Fox AD, Williams DJ, et al. Experience with heparin-bonded collagen-coated grafts for infrainguinal bypass. Cardiovasc Surg. 1999;7:491–494
  26. Warkentin TE. Heparin-induced thrombocytopenia and its treatment. J Thromb Thrombolysis. 2000;9(Suppl 1):S29–S35

PII: S0890-5096(07)00288-9

doi: 10.1016/j.avsg.2007.07.016

Annals of Vascular Surgery
Volume 21, Issue 6 , Pages 719-722 , November 2007

Article Tools

* Image Usage & Resolution